Thorn Medical PLC Joint Venture to Provide Stem Cell Cure for Baldness

LONDON, April 5, 2016 /PRNewswire/ --

Thorn Medical PLC ("Thorn" or the "Company"), the international healthcare group, today announces the launch of a joint venture company, "Tricogeneca Limited", with IK Clinics Founder and Director Dr Irum Khan, which will provide stem cell treatments for baldness.

Capitalising on Thorn Medical's recently acquired Stem Cell Therapy and Research licence in the Bahamas, the company plans to establish its first Tricogeneca Hair Loss treatment centre in the Bahamas, with further centres being established globally.

Jack Kaye, Thorn Medical's CEO said: "We are delighted to establish this joint venture with Dr Khan. She has had great success in using Stem Cells for hair regrowth and we are keen to further promote this amazing breakthrough to make it available internationally, whilst carrying out further on-going development."

Dr Khan said: "Our initial focus has been on treating men, where we've had a 100% success rate and we're now refining our techniques for curing Alopecia in women, which, although still at an early stage, has so far shown similar success."

Dr Khan adds: "In addition to allowing us to provide cures for baldness on a commercial scale using Thorn Medical's Stem Cell licence and treatment facility in the Bahamas, our joint venture will give us access to their state of the art development facility to extend our Stem Cell work in Regenerative Medicine to include inflammatory and autoimmune skin diseases.

Dr Mahmood Bashir, who heads up Thorn Medical's Stem Cell development and treatment efforts, said: "Although current techniques are still in their infancy, with only 10% of the new hair follicles cultured remaining alive, we can culture sufficient quantities in the lab to provide a complete cure for male pattern baldness."

As Mr Kaye sums it up: "With our recent Stem Cell licence in the Bahamas and this new venture, male pattern baldness will soon be a thing of the past!"

THE DIRECTORS OF THE ISSUER ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT

Note to Editors 

Thorn Medical PLC 

Thorn Medical is a trusted expert investor and acceleration partner dedicated to breaking down the barriers to providing more efficient and effective healthcare worldwide.

With a clear focus on improving human wellbeing, it acts as an aggregator of innovative, scientifically-validated medical technology, pharmaceutical products and healthcare services businesses.

It aims to transform organisational performance through delivering best practice flexible management services that streamline operations, reduce costs, encourage cross-fertilisation, expand market reach and enhance return on capital.

Thorn Medical is dedicated to this market, with a global perspective and an understanding at first hand of the evolving challenges that healthcare businesses face in growing successfully.

Thorn Medical understands how to create value for investors, service providers and patients through building a balanced portfolio of pre-and post-revenue companies that specialise in commercialising innovative and medical technologies and services.

Thorn Medical will continue to grow both organically and through acquisitions, continually developing the enterprise and fully addressing the human health cycle and its genetic, environmental, physical and nutritional influencing factors.

Thorn Medical focuses on four areas

• Disease prevention
• Immunity optimisation
• Disease treatment
• Research & development

For further information, please visit Thorn Medical's website http://www.thornmedical.com

Contact:    
Henry Gewanter, Thorn Medical PLC
Tel: +44(0)7774-228845